Research programme: HIV tat inhibitors - Amgen
Alternative Names: HIV tat inhibitors research programme - AmgenLatest Information Update: 09 Dec 2003
Price :
$50 *
At a glance
- Originator Tularik
- Class Small molecules
- Mechanism of Action HIV replication inhibitors; Human immunodeficiency virus tat gene product inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 09 Dec 2003 Discontinued - Preclinical for HIV infections treatment in USA (PO)
- 10 Mar 1999 Preclinical development for HIV infections treatment in USA (PO)